Challenges of up-scaling lentivirus production and processing

Journal of Biotechnology

Volumn 240, Issue , 2016, Pages 23-30

  McCarron, Alexandra ^a,b,c   Donnelley, Martin ^a,b,c   McIntyre, Chantelle ^a,b,c   Parsons, David ^a,b,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Gene therapy; Lentiviral vector; Production; Purification; Scale up

Indexed keywords

CELL CULTURE; GENE TRANSFER; GENES; MOLECULAR BIOLOGY; PRODUCTION; PURIFICATION; VECTORS;

ADHERENT CELLS; LENTIVIRAL VECTOR; PROCESSING APPROACH; QUALITY ASSESSMENT; SCALE-UP; STABLE CELL LINES; TRANSFER VEHICLES; TRANSIENT TRANSFECTION;

GENE THERAPY;

LENTIVIRUS VECTOR;

ADHERENT CELL; ADSORPTION CHROMATOGRAPHY; AFFINITY ADSORPTION CHROMATOGRAPHY; ANION EXCHANGE CHROMATOGRAPHY; CELL CULTURE; CELL LINE; CELL SUSPENSION; CONCENTRATION TECHNIQUE; DOWNSTREAM PROCESSING; FIXED BED REACTOR; GENE THERAPY; GENE TRANSFER; HOLLOW FIBER REACTOR; LARGE SCALE PRODUCTION; LENTIVIRINAE; MICROCARRIER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROCEDURES; PROCESSING; PURIFICATION; QUALITY CONTROL; REVIEW; SAFETY; SCALE UP; SIZE EXCLUSION CHROMATOGRAPHY; TANGENTIAL FLOW FILTRATION; TRANSIENT TRANSFECTION; ULTRACENTRIFUGATION; ANIMAL; CELL CULTURE TECHNIQUE; GENE VECTOR; GENETICS; HUMAN;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS;

EID: 84992602696     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2016.10.016     Document Type: Review

References (55)

1. Naldini, L., Blomer, U., Gallay, P., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996), 263–267, 10.1126/science.272.5259.263.
2. Sinn, P.L., Sauter, S.L., McCray, P.L., Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors – design, biosafety, and production. Gene Ther. 12 (2005), 1089–1098, 10.1038/sj.gt.3302570.
3. Hematti, P., Hong, B.-K., Ferguson, C., et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol., 2, 2004, e423, 10.1371/journal.pbio.0020423.
4. Cronin, J., Zhang, X.Y., Reiser, J., Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 5 (2005), 387–398.
5. Cmielewski, P., Donnelley, M., Parsons, D.W., Long-term therapeutic and reporter gene expression in lentiviral vector treated cystic fibrosis mice. J. Gene Med. 16 (2014), 291–299, 10.1002/jgm.2778.
6. De Ravin, S.S., Wu, X., Moir, S., et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med., 8, 2016.
7. Bank, A., Dorazio, R., Leboulch, P., A Phase I/II Clinical Trial of Beta-Globin Gene Therapy for Beta-Thalassemia. Vichinsky, E.P., (eds.), 2005, 308–316.
8. Palfi, S., Gurruchaga, J.M., Ralph, G.S., et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383 (2014), 1138–1146, 10.1016/s0140-6736(13)61939-x.
9. Gu, Y., Hou, W., Xu, C., Li, S., Shih, J.W.K., Xia, N., The enhancement of RNAi against HIV in vitro and in vivo using H-2K(k) protein as a sorting method. J. Virol. Methods 182 (2012), 9–17, 10.1016/j.jviromet.2012.02.007.
10. Neschadim, A., Wang, J.C.M., Lavie, A., Medin, J.A., Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. Cancer Gene Ther. 19 (2012), 320–327, 10.1038/cgt.2012.4.
11. Schweizer, M., Merten, O.W., Large-scale production means for the manufacturing of lentiviral vectors. Curr. Gene Ther. 10 (2010), 474–486, 10.2174/156652310793797748.
12. Segura, M.M., Mangion, M., Gaillet, B., Garnier, A., New developments in lentiviral vector design, production and purification. Expert Opin. Biol. Ther. 13 (2013), 987–1011, 10.1517/14712598.2013.779249.
13. Smith, S.L., Shioda, T., Advantages of COS-1 monkey kidney epithelial cells as packaging host for small-volume production of high-quality recombinant lentiviruses. J. Virol. Methods 157 (2009), 47–54, 10.1016/j.jviromet.2008.12.002.
14. Stewart, H.J., Leroux-Carlucci, M.A., Sion, C.J.M., Mitrophanous, K.A., Radcliffe, P.A., Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther. 16 (2009), 805–814, 10.1038/gt.2009.20.
15. Sanber, K.S., Knight, S.B., Stephen, S.L., et al. Construction of stable packaging cell lines for clinical lentiviral vector production. Sci. Rep., 5, 2015, 10.1038/srep09021.
16. Segura, M.M., Garnier, A., Durocher, Y., Coelho, H., Kamen, A., Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol. Bioeng. 98 (2007), 789–799, 10.1002/bit.21467.
17. van der Loo, J.C.M., Swaney, W.P., Grassman, E., et al. Scale-up and manufacturing of clinical-grade self-inactivating gamma-retroviral vectors by transient transfection. Gene Ther. 19 (2012), 246–254, 10.1038/gt.2011.102.
18. ® single-use fixed-bed bioreactor, from bench-scale to industrial scale. BMC Proc., 7, 2013, P59, 10.1186/1753-6561-7-S6-P59.
19. Merten, O.-W., Hebben, M., Bovolenta, C., Production of lentiviral vectors. Mol. Ther. Methods Clin. Dev., 3, 2016, 16017, 10.1038/mtm.2016.17.
20. Reed, S.E., Staley, E.M., Mayginnes, J.P., Pintel, D.J., Tullis, G.E., Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J. Virol. Methods 138 (2006), 85–98, 10.1016/j.jviromet.2006.07.024.
21. Cribbs, A.P., Kennedy, A., Gregory, B., Brennan, F.M., Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. BMC Biotechnol., 2013, 13, 10.1186/1472-6750-13-98.
22. Segura, M.M., Garnier, A., Durocher, Y., Ansorge, S., Kamen, A., New Protocol for Lentiviral Vector Mass Production. Federico, M., (eds.), 2010, 39–52.
23. Krieg, A.M., Direct immunologic activities of CpG DNA and implications for gene therapy. J. Gene Med. 1 (1999), 56–63, 10.1002/(SICI)1521-2254(199901/02)1:1<56:AID-JGM5>3.0.CO;2-6.
24. Stornaiuolo, A., Piovani, B.M., Bossi, S., et al. RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy. Hum. Gene Ther. Method 24 (2013), 228–240, 10.1089/hgtb.2012.190.
25. Throm, R.E., Ouma, A.A., Zhou, S., et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113 (2009), 5104–5110, 10.1182/blood-2008-11-191049.
26. Ikeda, Y., Takeuchi, Y., Martin, F., Cosset, F.L., Mitrophanous, K., Collins, M., Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21 (2003), 569–572, 10.1038/nbt815.
27. Merten, O.-W., Advances in cell culture: anchorage dependence. Philos. Trans. R. Soc. B, 2015, 370, 10.1098/rstb.2014.0040.
28. Tapia, F., Vogel, T., Genzel, Y., et al. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor. Vaccine 32 (2014), 1003–1011, 10.1016/j.vaccine.2013.11.044.
29. Sheu, J., Beltzer, J., Fury, B., et al. Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor. Mol. Ther. Methods Clin. Dev., 2, 2015, 15020, 10.1038/mtm.2015.20.
30. Wang, X., Olszewska, M., Qu, J., et al. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. J. Immunother. 38 (2015), 127–135, 10.1097/cji.0000000000000072.
31. Chaubard, J.F., Asselot, L., Benoist, S., et al. Vector production for human gene therapy – commerical-scale production of adenovirus in serum-free suspension. Genet. Eng. News, 20, 2000, 48.
32. Merten, O.W., Cruz, P.E., Rochette, C., et al. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol. Prog. 17 (2001), 326–335, 10.1021/bp000162z.
33. Merten, O.W., State-of-the-art of the production of retroviral vectors. J. Gene Med. 6 (2004), S105–S124, 10.1002/jgm.499.
34. Wu, S.C., Huang, G.Y.L., Liu, J.H., Production of retrovirus and adenovirus vectors for gene therapy: a comparative study using microcarrier and stationary cell culture. Biotechnol. Prog. 18 (2002), 617–622, 10.1021/bp020026p.
35. Ghani, K., Cottin, S., Kamen, A., Caruso, M., Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media. Gene Ther. 14 (2007), 1705–1711, 10.1038/sj.gt.3303039.
36. Geraerts, M., Michiels, M., Baekelandt, V., Debyser, Z., Gijsbers, R., Upscaling of lentiviral vector production by tangential flow filtration. J. Gene Med. 7 (2005), 1299–1310, 10.1002/jgm.778.
37. Ansorge, S., Lanthier, S., Transfiguracion, J., Durocher, Y., Henry, O., Kamen, A., Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene Med. 11 (2009), 868–876, 10.1002/jgm.1370.
38. Marceau, N., Gasmi, M., 2013. Scalable lentiviral vector production system compatible with industrial pharmaceutical applications. WO 2013076309 A1.
39. Rodrigues, T., Carrondo, M.J.T., Alves, P.M., Cruz, P.E., Purification of retroviral vectors for clinical application: biological implications and technological challenges. J. Biotechnol. 127 (2007), 520–541, 10.1016/j.jbiotec.2006.07.028.
40. Kutner, R.H., Puthli, S., Marino, M.P., Ramsay, A., Reiser, J., Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. Mol. Ther., 17, 2009, S274.
41. Transfiguracion, J., Jaalouk, D.E., Ghani, K., Galipeau, J., Kamen, A., Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum. Gene Ther. 14 (2003), 1139–1153.
42. Scherr, M., Battmer, K., Eder, M., et al. Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther. 9 (2002), 1708–1714, 10.1038/sj.gt.3301848.
43. Marino, M.P., Luce, M.J., Reiser, J., Small- to large-scale production of lentivirus vectors. Methods Mol. Biol. (Clifton, N.J.) 229 (2003), 43–55.
44. Zimmermann, K., Scheibe, O., Kocourek, A., Muelich, J., Jurkiewicz, E., Pfeifer, A., Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltration. BMC Biotechnol., 2011, 11, 10.1186/1472-6750-11-55.
45. Segura, M.D., Kamen, A., Trudel, P., Garnier, A., A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol. Bioeng. 90 (2005), 391–404.
46. Merten, O.-W., Charrier, S., Laroudie, N., et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum. Gene Ther. 22 (2011), 343–356, 10.1089/hum.2010.060.
47. Summerford, C., Samulski, R.J., Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat. Med. 5 (1999), 587–588.
48. Reiser, J., Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 7 (2000), 910–913, 10.1038/sj.gt.3301188.
49. Ichim, C.V., Wells, R.A., Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation. J. Transl. Med., 9, 2011, 137, 10.1186/1479-5876-9-137.
50. Aiuti, A., Biasco, L., Scaramuzza, S., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 2013, 865-U871, 10.1126/science.1233151.
51. Biffi, A., Montini, E., Lorioli, L., et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 2013, 864-U858, 10.1126/science.1233158.
52. Sastry, L., Johnson, T., Hobson, M.J., Smucker, B., Cornetta, K., Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 9 (2002), 1155–1162, 10.1038/sj.gt.3301731.
53. Escarpe, P., Zayek, N., Chin, P., et al. Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. Mol. Ther. 8 (2003), 332–341, 10.1016/s1525-0016(03)00167-0-9.
54. Cornetta, K., Yao, J., Jasti, A., et al. Replication-competent lentivirus analysis of clinical grade vector products. Mol. Ther. 19 (2011), 557–566, 10.1038/mt.2010.278.
55. Sastry, L., Xu, Y., Duffy, L., et al. Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection. Hum. Gene Ther. 16 (2005), 1227–1236, 10.1089/hum.2005.16.1227.